Sonoda K-H, Enaida H, Ueno A, Nakamura T, Kawano Y-I, Kubota T, Sakamoto T, Ishibashi T
Department of Ophthalmology, Kyushu University Graduate School of Medicine, Fukuoka, Japan.
Br J Ophthalmol. 2003 Aug;87(8):1010-4. doi: 10.1136/bjo.87.8.1010.
To examine the outcome of a triamcinolone acetonide (TA) assisted pars plana vitrectomy (PPV) for refractory uveitis.
Six patients suffering from proliferative vitreoretinopathy (PVR) with refractory uveitis underwent a TA assisted PPV. The patients consisted of one with Vogt-Koyanagi-Harada disease, one with acute retinal necrosis, one with Behçet's disease, and three with sarcoidosis. TA was inoculated into the vitreous cavity to visualise the vitreous. In four of six patients, 4 mg of TA were intentionally left in the vitreous cavity to reduce the degree of postoperative inflammation.
The vitreous body was clearly seen using TA during surgery, which greatly helped us to perform a posterior hyaloid resection safely and thoroughly. As we previously observed in other disease, TA allowed us to visualise the transparent vitreous and thus was helpful in removing the vitreous cortex from the retina completely in uveitis. One patient (Behçet's disease, in whom TA was intentionally left) showed an elevated intraocular pressure (IOP) transiently after surgery which was controllable by topical eye drops. The remaining TA diminished day by day and had almost completely disappeared within a month from operation.
TA improved the visibility of the hyaloid and the safety of the surgical procedures and no serious complications were observed after TA assisted PPV in uveitis. Although the long term effects are still unknown, this method appears to be potentially useful as an improved treatment for PVR associated with refractory uveitis.
探讨曲安奈德(TA)辅助的玻璃体切除术(PPV)治疗难治性葡萄膜炎的疗效。
6例患有增殖性玻璃体视网膜病变(PVR)合并难治性葡萄膜炎的患者接受了TA辅助的PPV。患者包括1例Vogt-小柳原田病患者、1例急性视网膜坏死患者、1例白塞病患者和3例结节病患者。将TA注入玻璃体腔以使玻璃体可视化。在6例患者中的4例中,故意在玻璃体腔中留置4mg TA以减轻术后炎症程度。
手术期间使用TA可清晰看到玻璃体,这极大地帮助我们安全、彻底地进行后玻璃体膜切除术。正如我们之前在其他疾病中观察到的,TA使我们能够看到透明的玻璃体,因此有助于在葡萄膜炎中从视网膜完全清除玻璃体皮质。1例患者(白塞病,故意留置了TA)术后眼压短暂升高,可通过局部滴眼液控制。其余的TA逐日减少,在手术后1个月内几乎完全消失。
TA提高了玻璃体膜的可视性和手术操作的安全性,TA辅助的PPV治疗葡萄膜炎后未观察到严重并发症。尽管长期效果尚不清楚,但这种方法似乎可能作为一种改良的治疗方法用于治疗与难治性葡萄膜炎相关的PVR。